Literature DB >> 11557454

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

S Perea1, J L López-Ribot, W R Kirkpatrick, R K McAtee, R A Santillán, M Martínez, D Calabrese, D Sanglard, T F Patterson.   

Abstract

Molecular mechanisms of azole resistance in Candida albicans, including alterations in the target enzyme and increased efflux of drug, have been described, but the epidemiology of the resistance mechanisms has not been established. We have investigated the molecular mechanisms of resistance to azoles in C. albicans strains displaying high-level fluconazole resistance (MICs, > or =64 microg/ml) isolated from human immunodeficiency virus (HIV)-infected patients with oropharyngeal candidiasis. The levels of expression of genes encoding lanosterol 14alpha-demethylase (ERG11) and efflux transporters (MDR1 and CDR) implicated in azole resistance were monitored in matched sets of susceptible and resistant isolates. In addition, ERG11 genes were amplified by PCR, and their nucleotide sequences were determined in order to detect point mutations with a possible effect in the affinity for azoles. The analysis confirmed the multifactorial nature of azole resistance and the prevalence of these mechanisms of resistance in C. albicans clinical isolates exhibiting frank fluconazole resistance, with a predominance of overexpression of genes encoding efflux pumps, detected in 85% of all resistant isolates, being found. Alterations in the target enzyme, including functional amino acid substitutions and overexpression of the gene that encodes the enzyme, were detected in 65 and 35% of the isolates, respectively. Overall, multiple mechanisms of resistance were combined in 75% of the isolates displaying high-level fluconazole resistance. These results may help in the development of new strategies to overcome the problem of resistance as well as new treatments for this condition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557454      PMCID: PMC90716          DOI: 10.1128/AAC.45.10.2676-2684.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  T J Walsh; C E Gonzalez; S Piscitelli; J D Bacher; J Peter; R Torres; D Shetti; V Katsov; K Kligys; C A Lyman
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

Review 3.  Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; D Bellens; H Moereels; P A Janssen
Journal:  Biochem Soc Trans       Date:  1990-02       Impact factor: 5.407

Review 4.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

5.  Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.

Authors:  Patrick Marichal; Luc Koymans; Staf Willemsens; Danny Bellens; Peter Verhasselt; Walter Luyten; Marcel Borgers; Frans C S Ramaekers; Frank C Odds; Hugo Vanden Bossche
Journal:  Microbiology       Date:  1999-10       Impact factor: 2.777

6.  Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.

Authors:  D Sanglard; F Ischer; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 7.  Molecular mechanisms of drug resistance in fungi.

Authors:  H Vanden Bossche; P Marichal; F C Odds
Journal:  Trends Microbiol       Date:  1994-10       Impact factor: 17.079

Review 8.  Genetics and biochemistry of yeast multidrug resistance.

Authors:  E Balzi; A Goffeau
Journal:  Biochim Biophys Acta       Date:  1994-08-30

9.  Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals.

Authors:  R Prasad; P De Wergifosse; A Goffeau; E Balzi
Journal:  Curr Genet       Date:  1995-03       Impact factor: 3.886

10.  Modeling cytochrome P450 14 alpha demethylase (Candida albicans) from P450cam.

Authors:  P E Boscott; G H Grant
Journal:  J Mol Graph       Date:  1994-09
View more
  171 in total

1.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

2.  Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients.

Authors:  Ali Abdul Lattif; Uma Banerjee; Rajendra Prasad; Ashutosh Biswas; Naveet Wig; Neeraj Sharma; Absarul Haque; Nivedita Gupta; Najma Z Baquer; Gauranga Mukhopadhyay
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

3.  Oropharyngeal colonization of HIV-infected outpatients in Taiwan by yeast pathogens.

Authors:  Yun-Liang Yang; Chien-Ching Hung; An-Huei Wang; Fan-Chen Tseng; Shiang Ning Leaw; Yu-Tzu Tseng; Chia-Li Su; Hui-Ting Chen; Tsai-Ling Lauderdale; Hsiu-Jung Lo
Journal:  J Clin Microbiol       Date:  2010-05-05       Impact factor: 5.948

4.  Regulatory Role of ERG3 and Efg1 in Azoles-Resistant Strains of Candida albicans Isolated from Patients Diagnosed with Vulvovaginal Candidiasis.

Authors:  Wenli Feng; Jing Yang; Zhiqin Xi; Ying Ji; Xin Zhu; Lu Yang; Yan Ma
Journal:  Indian J Microbiol       Date:  2019-11-02       Impact factor: 2.461

5.  Candida albicans flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity.

Authors:  Rui Li; Rohitashw Kumar; Swetha Tati; Sumant Puri; Mira Edgerton
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

Review 6.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms.

Authors:  Semanti Sarkar; Priya Uppuluri; Christopher G Pierce; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

8.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.

Authors:  Donna M MacCallum; Alix Coste; Françoise Ischer; Mette D Jacobsen; Frank C Odds; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

10.  Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.

Authors:  John-Paul Vermitsky; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.